Literature DB >> 29030770

Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies.

Francesca Andreetta1, Elena Rinaldi2, Emanuela Bartoccioni3, Anna Pia Riviera4, Elena Bazzigaluppi5, Raffella Fazio5, Giovanni Deiana6, Alessandro Pini7, Maria Grazia Giudizi8, Fulvio Baggi2.   

Abstract

This paper presents the Italian guidelines for autoantibody testing in myasthenia gravis that have been developed following a consensus process built on questionnaire-based surveys, internet contacts and discussions during dedicated workshops of the sponsoring Italian Association of Neuroimmunology (AINI). Essential clinical information on myasthenic syndromes, indications and limits of antibody testing, instructions for result interpretation and an agreed laboratory protocol (Appendix) are reported for the communicative community of neurologists and clinical pathologists.

Entities:  

Keywords:  AChR; Laboratory diagnostics; MuSK; Myasthenia gravis; Neurological autoimmune diseases

Mesh:

Substances:

Year:  2017        PMID: 29030770     DOI: 10.1007/s10072-017-3026-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  17 in total

1.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.

Authors:  W Hoch; J McConville; S Helms; J Newsom-Davis; A Melms; A Vincent
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

2.  The fetal/adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis as a marker for transfer of the disease to the newborn.

Authors:  M Gardnerova; B Eymard; E Morel; M Faltin; J Zajac; O Sadovsky; P Tripon; M Domergue; B Vernet-der Garabedian; J F Bach
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

3.  Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.

Authors:  Osamu Higuchi; Johko Hamuro; Masakatsu Motomura; Yuji Yamanashi
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

4.  Myasthenia gravis: comparative autoantibody assays using human muscle, TE671, and glucocorticoid-treated TE671 cells as sources of antigen.

Authors:  P F Kennel; J T Vilquin; S Braun; P Fonteneau; J M Warter; P Poindron
Journal:  Clin Immunol Immunopathol       Date:  1995-03

5.  Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients.

Authors:  H J Oosterhuis; P C Limburg; E Hummel-Tappel; T H The
Journal:  J Neurol Sci       Date:  1983-03       Impact factor: 3.181

6.  Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671.

Authors:  R Voltz; R Hohlfeld; A Fateh-Moghadam; T N Witt; M Wick; C Reimers; B Siegele; H Wekerle
Journal:  Neurology       Date:  1991-11       Impact factor: 9.910

Review 7.  An update on laboratory diagnosis in myasthenia gravis.

Authors:  Joel Oger; Hans Frykman
Journal:  Clin Chim Acta       Date:  2015-08-01       Impact factor: 3.786

8.  Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen.

Authors:  A Vincent; C Newland; L Brueton; D Beeson; S Riemersma; S M Huson; J Newsom-Davis
Journal:  Lancet       Date:  1995-07-01       Impact factor: 79.321

9.  Clinical aspects of MuSK antibody positive seronegative MG.

Authors:  D B Sanders; K El-Salem; J M Massey; J McConville; A Vincent
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

10.  An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.

Authors:  J Lindstrom
Journal:  Clin Immunol Immunopathol       Date:  1977-01
View more
  2 in total

Review 1.  Receptor autoimmunity: diagnostic and therapeutic implications.

Authors:  Renato Tozzoli
Journal:  Auto Immun Highlights       Date:  2020-01-07

2.  Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program.

Authors:  Matteo Gastaldi; Elisabetta Zardini; Silvia Scaranzin; Antonio Uccelli; Francesca Andreetta; Fulvio Baggi; Diego Franciotta
Journal:  Front Neurol       Date:  2020-01-14       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.